“…Most previous studies have only evaluated skeletal MM without assessing HGS in patients with HCC treated with sorafenib [ 10 , 11 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ]. As shown in Table 1 , skeletal muscle depletion (low MM) is a poor prognostic factor for OS in most studies [ 10 , 22 , 23 , 24 , 26 , 28 , 31 , 32 ], while there was no significant difference in others [ 11 , 27 , 29 ]. The subgroup analyses showed that the OS of patients who had two or more negative prognostic factors (albumin ≤3.5 g/dL, alpha-fetoprotein ≥100 ng/mL, lesions in bilateral hepatic lobes, or major portal vein invasions) with low MM was significantly shorter than in those with high MM [ 27 ], and the combined presence of low MM and low total adipose tissue index was significantly associated with worse OS [ 29 ].…”